Jason Bednar
Stock Analyst at Piper Sandler
(2.43)
# 2,349
Out of 4,783 analysts
162
Total ratings
42.75%
Success rate
-0.75%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALGN Align Technology | Reiterates: Overweight | $270 → $235 | $164.29 | +43.04% | 29 | Mar 18, 2025 | |
| COO The Cooper Companies | Reiterates: Overweight | $120 → $115 | $84.98 | +35.33% | 12 | Mar 7, 2025 | |
| SOLV Solventum | Maintains: Neutral | $75 → $84 | $75.51 | +11.24% | 3 | Feb 28, 2025 | |
| MASI Masimo | Maintains: Overweight | $210 → $215 | $168.47 | +27.62% | 14 | Feb 26, 2025 | |
| KRMD KORU Medical Systems | Downgrades: Neutral | $4.5 | $2.61 | +72.41% | 6 | Feb 14, 2025 | |
| STE STERIS | Maintains: Overweight | $260 → $265 | $224.23 | +18.18% | 9 | Feb 3, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $18 | $18.03 | -0.17% | 11 | Feb 3, 2025 | |
| MMSI Merit Medical Systems | Reiterates: Overweight | $114 → $116 | $103.27 | +12.33% | 9 | Jan 29, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $275 → $280 | $228.71 | +22.43% | 7 | Jan 28, 2025 | |
| NVCR NovoCure | Maintains: Overweight | $28 → $42 | $18.97 | +121.40% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $24 | $31.25 | -23.20% | 9 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $1.52 | +294.74% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $2.66 | +163.16% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3.5 → $1 | $0.28 | +255.75% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $6.79 | +76.73% | 10 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 | $69.40 | +23.92% | 6 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $13 | $11.80 | +10.17% | 1 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $35 → $32 | $15.64 | +104.60% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $507.90 | -26.76% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $9 | $2.22 | +305.41% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $81.66 | +16.34% | 1 | Apr 19, 2023 |
Align Technology
Mar 18, 2025
Reiterates: Overweight
Price Target: $270 → $235
Current: $164.29
Upside: +43.04%
The Cooper Companies
Mar 7, 2025
Reiterates: Overweight
Price Target: $120 → $115
Current: $84.98
Upside: +35.33%
Solventum
Feb 28, 2025
Maintains: Neutral
Price Target: $75 → $84
Current: $75.51
Upside: +11.24%
Masimo
Feb 26, 2025
Maintains: Overweight
Price Target: $210 → $215
Current: $168.47
Upside: +27.62%
KORU Medical Systems
Feb 14, 2025
Downgrades: Neutral
Price Target: $4.5
Current: $2.61
Upside: +72.41%
STERIS
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $224.23
Upside: +18.18%
Envista Holdings
Feb 3, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $18.03
Upside: -0.17%
Merit Medical Systems
Jan 29, 2025
Reiterates: Overweight
Price Target: $114 → $116
Current: $103.27
Upside: +12.33%
Becton, Dickinson and Company
Jan 28, 2025
Maintains: Overweight
Price Target: $275 → $280
Current: $228.71
Upside: +22.43%
NovoCure
Dec 13, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $18.97
Upside: +121.40%
Dec 6, 2024
Maintains: Neutral
Price Target: $26 → $24
Current: $31.25
Upside: -23.20%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $1.52
Upside: +294.74%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $2.66
Upside: +163.16%
Aug 7, 2024
Maintains: Overweight
Price Target: $3.5 → $1
Current: $0.28
Upside: +255.75%
Aug 1, 2024
Maintains: Overweight
Price Target: $14 → $12
Current: $6.79
Upside: +76.73%
Jun 21, 2024
Reiterates: Overweight
Price Target: $86
Current: $69.40
Upside: +23.92%
May 21, 2024
Initiates: Neutral
Price Target: $13
Current: $11.80
Upside: +10.17%
May 3, 2024
Reiterates: Neutral
Price Target: $35 → $32
Current: $15.64
Upside: +104.60%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $507.90
Upside: -26.76%
Nov 10, 2023
Maintains: Overweight
Price Target: $14 → $9
Current: $2.22
Upside: +305.41%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $81.66
Upside: +16.34%